Evidence map›Paper›PMID 37786752›Full record

ArticleJournal of liver2020

Prevalence and Predictors of Nonalcoholic Steatohepatitis Using Multiple Non-Invasive Methods: Data from NHANES III.

Magda Shaheen, Katrina M Schrode, Dulcie Kermah, Deyu Pan, Vishwajeet Puri, Ali Zarrinpar, David Elisha, Sonia Michael Najjar, Theodore C Friedman

Open access · greenAbstract read
In one paragraph

Article in Journal of liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Magda ShaheenDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Katrina M SchrodeDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Dulcie KermahDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Deyu PanDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Vishwajeet PuriDepartment of Biomedical Sciences and Diabetes, Ohio University-Heritage College of Medicine, Athens, USA.
Ali ZarrinparDepartment of Surgery, University of Florida School of Medicine, Gainesville, USA.
David ElishaDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Sonia Michael NajjarDepartment of Biomedical Sciences and Diabetes, Ohio University-Heritage College of Medicine, Athens, USA.
Theodore C FriedmanDepartment of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, USA.
Charles R. Drew University of Medicine and Science · USUniversity of Florida · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Ali Andalibi, Jose A Torres-Ruiz · 2012 to 2026
$60.0M
Drew MIDARP (Infrastructure in Drug Abuse Research)R24DA017298 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2004 to 2018
$5.0M
Novel pathways in the pathogenesis and pathophysiology of NAFLD in HispanicsR01MD012579 · NIMHD · OHIO UNIVERSITY ATHENS · PI FRIEDMAN, THEODORE C, NAJJAR, SONIA M. · 2019 to 2023
$3.2M
The Next Generation Substance Abuse Research Training at Charles R. Drew University (CDU) and UCLA (NGSART-CU)R25DA050723 · NIDA · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI FRIEDMAN, THEODORE C · 2020 to 2024
$1.4M
NCATS NIH HHS UL1 TR001881NIDA NIH HHS R24 DA017298NIDA NIH HHS R25 DA050723NIMHD NIH HHS R01 MD012579NIMHD NIH HHS S21 MD000103NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

Objective: Patients with nonalcoholic steatohepatitis (NASH) are at risk for developing cirrhosis and hepatic cancer. Currently, the definitive gold-standard method of diagnosing NASH is a liver biopsy, an invasive and costly method. Our objective was to compare three non-invasive methods of identifying NASH by using data on 10,007 subjects from NHANES III (1988-1994) to determine the prevalence and variables associated with NASH, as defined by each non-invasive method. Methods: We used ultrasound data to identify subjects with moderate-to-severe hepatic steatosis, of whom we identified the NASH population using either the HAIR score, the NASH liver fat score, or the Gholam score, each of which had been validated with liver biopsy. We performed multinomial logistic regression to compare each NASH population to the normal population (those with no-to-mild hepatic steatosis). Results: We identified 1136 (9.5%) subjects as having NASH by at least one method and 219 (1.8%) were identified by all 3 methods. Independent of the non-invasive method used, Mexican-Americans (MA) had the highest prevalence of NASH. All three methods identified significant risk factors for NASH (p<0.05), including: elevated waist-to-hip ratio, elevated levels of C-peptide, total cholesterol, or C-reactive protein (CRP). Conclusion: We conclude that the combined non-invasive methods can help identify candidates with a high likelihood of being diagnosed with NASH. Health care providers can screen people with the combined non-invasive methods for the risk factors and identify candidates for interventions, including exercise and/or referral to biopsy.

Indexed as

NHANES IIINon-alcoholic fatty liverNonalcoholic steatohepatitisNon-invasive methodsObesity

Identifiers

PMID37786752
PMCPMC10544753
OpenAlexW3122112468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.